Sydney, May 19, 2026, 09:03 (AEST)
ALS Ltd is set to face another test at Tuesday’s ASX open after shares slipped 1.7% Monday. This drop came even as the laboratory-testing company posted record annual earnings and boosted its dividend. Shares ended at A$21.83, trading in a range from A$21.32 to A$22.90 for the day.
Market focus is on ALS after it posted profit growth that met what investors wanted, but the share price is weighing if next year will keep pace. ALS reported revenue up 10.7% to A$3.32 billion for the year to March 31. Underlying NPAT — net profit after tax before significant items — climbed 25.8% to A$381.2 million, the company said.
ASX cash trading hadn’t started at the time of filing, with the market still in pre-open. Brokers are allowed to put in orders from 7:00 a.m. up to 9:59 a.m. Sydney time, according to ASX, but no trades match until the market opens. Normal trading runs from 09:59:45 to 16:00.
Core numbers came in strong. Underlying EBIT was up 19.3% to A$599.0 million, with the margin up 129 basis points to 18.0%. That’s operating profit before financing and tax, as adjusted by the company.
Commodities carried the quarter, with revenue there up 18.8% to A$1.29 billion. Minerals organic revenue climbed 20.2%, meaning growth came from the core business, not acquisitions. Minerals margin hit 33.0% as sample volumes climbed and pricing stayed solid while exploration picked up.
Life Sciences numbers were mixed. Revenue climbed 6.0%, Food was up 7.2%, but Environmental had weaker trades in the Americas and Pharmaceutical organic revenue dropped 1.6%. ALS said it’s working on fixing some problems in the Americas.
ALS chairman Nigel Garrard said there were “more buoyant conditions” in mineral exploration. CEO Malcolm Deane pointed to portfolio “resilience” and “disciplined operational execution.” On the results call, Deane told analysts ALS had hit its FY27 targets “12 months early,” mostly through organic growth. Company Announcements
The board set a final dividend at 23.1 cents a share, with 30% franking. Franking gives a tax credit on dividends in Australia. The total dividend for the year moves up to 42.5 cents, a gain of 10.1% from FY25. Payment is due July 3 for shareholders registered by June 15.
ALS is looking for mid- to high-single-digit organic revenue growth for FY27, keeping margin expansion about in line with FY26. The company sees Minerals organic revenue growth between 13% and 15%, while Life Sciences is aiming for mid-single-digit organic revenue growth and an extra 30 to 50 basis points of margin improvement.
But the risk isn’t hard to see. Environmental trading is still weak in the Americas. Supply chain trouble from the Middle East conflict and tariff changes could pose an earnings hit of A$5 million to A$10 million. Every 1% swing in major currencies against the Australian dollar is expected to move underlying EBIT by A$3 million and underlying NPAT by A$2 million. If mineral exploration spend drops, investors could move past the record FY26 numbers in a hurry.
ALS is grouped with testing giants like SGS, Bureau Veritas and Intertek, but its Monday update focused mostly on natural-resources testing. Commodities made up just under 40% of ALS’s revenue, and almost two-thirds of its underlying EBIT, going by company division numbers.
Australian stocks offered little support. The S&P/ASX 200 dropped 1.45% to 8,505.3 on Monday, hit by losses in materials and industrials. ALS faces a market already uneasy about cyclicals. Tuesday’s open will test whether the slide is just profit-taking after gains, or an early sign investors doubt FY27 growth.
